Signal transduction inhibition of APCs diminishes Th17 and Th1 responses in experimental autoimmune encephalomyelitis

Journal of Immunology

Volumn 182, Issue 7, 2009, Pages 4192-4199

  Skarica, Mario ^a   Wang, Tianhong ^a   McCadden, Erin ^a   Kardian, David ^a   Calabresi, Peter A ^b   Small, Donald ^a,b   Whartenby, Katharine A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 23; INTERLEUKIN 6; LESTAURTINIB; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; CARBAZOLE DERIVATIVE; CD135 ANTIGEN; CYTOKINE; ENZYME INHIBITOR; FLT3 PROTEIN, MOUSE; INTERLEUKIN 17;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TH1 CELL; TH17 CELL; ANIMAL; BIOSYNTHESIS; BRAIN; DRUG EFFECT; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; T LYMPHOCYTE SUBPOPULATION; WESTERN BLOTTING;

ANIMALS; ANTIGEN-PRESENTING CELLS; BLOTTING, WESTERN; BRAIN; CARBAZOLES; CHEMOTAXIS, LEUKOCYTE; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENZYME INHIBITORS; FEMALE; FMS-LIKE TYROSINE KINASE 3; INTERLEUKIN-17; MICE; MICROGLIA; SIGNAL TRANSDUCTION; T-LYMPHOCYTE SUBSETS; TH1 CELLS;

EID: 64249103526     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0803631     Document Type: Article

References (58)

1. de Vos, A. F., M. van Meurs, H. P. Brok, L. A. Boven, R. Q. Hintzen, P. van der Valk, R. Ravid, S. Rensing, L. Boon, B. A. 't Hart, and J. D. Laman. 2002. Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. 169: 5415-5423.
2. Juedes, A. E., and N. H. Ruddle. 2001. Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J. Immunol. 166: 5168-5175.
3. Miller, S. D., E. J. McMahon, B. Schreiner, and S. L. Bailey. 2007. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. NY Acad. Sci. 1103: 179-191.
4. McRae, B. L., C. L. Vanderlugt, M. C. Dal Canto, and S. D. Miller. 1995. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182: 75-85.
5. Vanderlugt, C. L., W. S. Begolka, K. L. Neville, Y. Katz-Levy, L. M. Howard, T. N. Eagar, J. A. Bluestone, and S. D. Miller. 1998. The functional significance of epitope spreading and its regulation by co-stimulatory molecules. Immunol. Rev. 164: 63-72.
6. McMahon, E. J., S. L. Bailey, C. V. Castenada, H. Waldner, and S. D. Miller. 2005. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 11: 335-339.
7. Tuohy, V. K., M. Yu, B. Weinstock-Guttman, and R. P. Kinkel. 1997. Diversity and plasticity of self recognition during the development of multiple sclerosis. J. Clin. Invest. 99: 1682-1690.
8. Guo, X., K. Nakamura, K. Kohyama, C. Harada, H. A. Behanna, D. M. Watterson, Y. Matsumoto, and T. Harada. 2007. Inhibition of glial cell activation ameliorates the severity of experimental autoimmune encephalomyelitis. Neurosci. Res. 59: 457-466. (Pubitemid 350007814)
9. Oppmann, B., R. Lesley, B. Blom, J. C. Timans, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al. 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13: 715-725.
10. Mensah-Brown, E. P., A. Shahin, M. Al-Shamisi, X. Wei, and M. L. Lukic. 2006. IL-23 leads to diabetes induction after subdiabetogenic treatment with multiple low doses of streptozotocin. Eur. J. Immunol. 36: 216-223.
11. Nakae, S., A. Nambu, K. Sudo, and Y. Iwakura. 2003. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J. Immunol. 171: 6173-6177. (Pubitemid 37467240)
12. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
13. Ifergan, I., H. Kebir, M. Bernard, K. Wosik, A. Dodelet-Devillers, R. Cayrol, N. Arbour, and A. Prat. 2008. The blood-brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 131: 785-799. (Pubitemid 351294709)
14. Becher, B., B. G. Durell, and R. J. Noelle. 2003. IL-23 produced by CNS-resident cells controls T cell encephalitogenicity during the effector phase of experimental autoimmune encephalomyelitis. J. Clin. Invest. 112: 1186-1191. (Pubitemid 38056295)
15. Ivanov, I. I., L. Zhou, and D. R. Littman. 2007. Transcriptional regulation of Th17 cell differentiation. Semin. Immunol. 19: 409-417. (Pubitemid 351274050)
16. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
17. Murphy, C. A., C. L. Langrish, Y. Chen, W. Blumenschein, T. McClanahan, R. A. Kastelein, J. D. Sedgwick, and D. J. Cua. 2003. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198: 1951-1957.
18. H17 and regulatory T cells. Nature 441: 235-238.
19. H17 lineage. Nature 441: 231-234.
20. Veldhoen, M., R. J. Hocking, C. J. Atkins, R. M. Locksley, and B. Stockinger. 2006. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24: 179-189. (Pubitemid 43214587)
21. H17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat. Immunol. 8: 967-974.
22. Levis, M., J. Allebach, K. F. Tse, R. Zheng, B. R. Baldwin, B. D. Smith, S. Jones-Bolin, B. Ruggeri, C. Dionne, and D. Small. 2002. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 99: 3885-3891. (Pubitemid 35332023)
23. Borges, L., R. E. Miller, J. Jones, K. Ariail, J. Whitmore, W. Fanslow, and D. H. Lynch. 1999. Synergistic action of fms-like tyrosine kinase 3 ligand and CD40 ligand in the induction of dendritic cells and generation of antitumor immunity in vivo. J. Immunol. 163: 1289-1297. (Pubitemid 29352746)
24. Lynch, D. H., A. Andreasen, E. Maraskovsky, J. Whitmore, R. E. Miller, and J. C. Schuh. 1997. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. 3: 625-631. (Pubitemid 27264971)
25. McKenna, H. J., K. L. Stocking, R. E. Miller, K. Brasel, T. De Smedt, E. Maraskovsky, C. R. Maliszewski, D. H. Lynch, J. Smith, B. Pulendran, et al. 2000. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood 95: 3489-3497.
26. Waskow, C., K. Liu, G. Darrasse-Jeze, P. Guermonprez, F. Ginhoux, M. Merad, T. Shengelia, K. Yao, and M. Nussenzweig. 2008. The receptor tyrosine kinase Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat. Immunol. 9: 676-683. (Pubitemid 351712638)
27. Whartenby, K. A., P. A. Calabresi, E. McCadden, B. Nguyen, D. Kardian, T. Wang, C. Mosse, D. M. Pardoll, and D. Small. 2005. Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc. Natl. Acad. Sci. USA 102: 16741-16746.
28. Greter, M., F. L. Heppner, M. P. Lemos, B. M. Odermatt, N. Goebels, T. Laufer, R. J. Noelle, and B. Becher. 2005. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 11: 328-334. (Pubitemid 40460562)
29. Hexner, E. O., C. Serdikoff, M. Jan, C. R. Swider, C. Robinson, S. Yang, T. Angeles, S. G. Emerson, M. Carroll, B. Ruggeri, and P. Dobrzanski. 2008. Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. Blood 111: 5663-5671.
30. Carmody, R. J., Q. Ruan, H. C. Liou, and Y. H. Chen. 2007. Essential roles of c-Rel in TLR-induced IL-23 p19 gene expression in dendritic cells. J. Immunol. 178: 186-191.
31. Parham, C., M. Chirica, J. Timans, E. Vaisberg, M. Travis, J. Cheung, S. Pflanz, R. Zhang, K. P. Singh, F. Vega, et al. 2002. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J. Immunol. 168: 5699-5708. (Pubitemid 34556153)
32. Kriehuber, E., W. Bauer, A. S. Charbonnier, D. Winter, S. Amatschek, D. Tamandl, N. Schweifer, G. Stingl, and D. Maurer. 2005. Balance between NF-κB and JNK/AP-1 activity controls dendritic cell life and death. Blood 106: 175-183. (Pubitemid 40967190)
33. Onishi, H., H. Kuroki, K. Matsumoto, E. Baba, N. Sasaki, H. Kuga, M. Tanaka, M. Katano, and T. Morisaki. 2004. Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-α through IL-12/TNF-α/NF-κB autocrine loop. Cancer Immunol. Immunother. 53: 1093-1100. (Pubitemid 39506398)
34. Rescigno, M., M. Martino, C. L. Sutherland, M. R. Gold, and P. Ricciardi-Castagnoli. 1998. Dendritic cell survival and maturation are regulated by different signaling pathways. J. Exp. Med. 188: 2175-2180. (Pubitemid 28562533)
35. Mann, J., F. Oakley, P. W. Johnson, and D. A. Mann. 2002. CD40 induces interleukin-6 gene transcription in dendritic cells: regulation by TRAF2, AP-1, NF-κB, and CBF1. J. Biol. Chem. 277: 17125-17138. (Pubitemid 34967745)
36. Lutz, M. B., N. Kukutsch, A. L. Ogilvie, S. Rossner, F. Koch, N. Romani, and G. Schuler. 1999. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 223: 77-92.
37. Curtin, J. F., G. D. King, C. Barcia, C. Liu, F. X. Hubert, C. Guillonneau, R. Josien, I. Anegon, P. R. Lowenstein, and M. G. Castro. 2006. Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J. Immunol. 176: 3566-3577.
38. Bettelli, E., M. Pagany, H. L. Weiner, C. Linington, R. A. Sobel, and V. K. Kuchroo. 2003. Myelin oligodendrocyte glycoprotein-specific T cell receptor transgenic mice develop spontaneous autoimmune optic neuritis. J. Exp. Med. 197: 1073-1081. (Pubitemid 36570063)
39. Kleinschek, M. A., A. M. Owyang, B. Joyce-Shaikh, C. L. Langrish, Y. Chen, D. M. Gorman, W. M. Blumenschein, T. McClanahan, F. Brombacher, S. D. Hurst, et al. 2007. IL-25 regulates Th17 function in autoimmune inflammation. J. Exp. Med. 204: 161-170. (Pubitemid 46148766)
40. Thakker, P., M. W. Leach, W. Kuang, S. E. Benoit, J. P. Leonard, and S. Marusic. 2007. IL-23 is critical in the induction but not in the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 178: 2589-2598. (Pubitemid 46233462)
41. Kroenke, M. A., and B. M. Segal. 2007. Th17 and Th1 responses directed against the immunizing epitope, as opposed to secondary epitopes, dominate the autoimmune repertoire during relapses of experimental autoimmune encephalomyelitis. J. Neurosci. Res. 85: 1685-1693.
42. Gocke, A. R., P. D. Cravens, L. H. Ben, R. Z. Hussain, S. C. Northrop, M. K. Racke, and A. E. Lovett-Racke. 2007. T-bet regulates the fate of Th1 and Th17 lymphocytes in autoimmunity. J. Immunol. 178: 1341-1348.
43. Kroenke, M. A., T. J. Carlson, A. V. Andjelkovic, and B. M. Segal. 2008. IL-12- and IL-23-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205: 1535-1541.
44. Serafini, B., S. Columba-Cabezas, F. Di Rosa, and F. Aloisi. 2000. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am. J. Pathol. 157: 1991-2002.
45. Ponomarev, E. D., L. P. Shriver, K. Maresz, and B. N. Dittel. 2005. Microglial cell activation and proliferation precedes the onset of CNS autoimmunity. J. Neurosci. Res. 81: 374-389.
46. Nessler, S., S. Boretius, C. Stadelmann, A. Bittner, D. Merkler, H. P. Hartung, T. Michaelis, W. Bruck, J. Frahm, N. Sommer, and B. Hemmer. 2007. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage. Brain 130: 2186-2198. (Pubitemid 47236612)
47. Ifergan, I., H. Kebir, M. Bernard, K. Wosik, A. Dodelet-Devillers, R. Cayrol, N. Arbour, and A. Prat. 2008. The blood brain barrier induces differentiation of migrating monocytes into Th17-polarizing dendritic cells. Brain 131: 785-799. (Pubitemid 351294709)
48. Kimura, A., T. Naka, and T. Kishimoto. 2007. IL-6-dependent and -independent pathways in the development of interleukin 17-producing T helper cells. Proc. Natl. Acad. Sci. USA 104: 12099-12104. (Pubitemid 47185636)
49. Kaplin, A. I., D. M. Deshpande, E. Scott, C. Krishnan, J. S. Carmen, I. Shats, T. Martinez, J. Drummond, S. Dike, M. Pletnikov, et al. 2005. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J. Clin. Invest. 115: 2731-2741.
50. Utsugi, M., K. Dobashi, T. Ishizuka, T. Kawata, T. Hisada, Y. Shimizu, A. Ono, and M. Mori. 2006. Rac1 negatively regulates lipopolysaccharide-induced IL-23 p19 expression in human macrophages and dendritic cells and NF-κB p65 trans activation plays a novel role. J. Immunol. 177: 4550-4557. (Pubitemid 44469786)
51. Ashton, A. W., G. M. Ware, D. K. Kaul, and J. A. Ware. 2003. Inhibition of tumor necrosis factor α-mediated NFκB activation and leukocyte adhesion, with enhanced endothelial apoptosis, by G protein-linked receptor (TP) ligands. J. Biol. Chem. 278: 11858-11866.
52. Keller, E. T., C. Chang, and W. B. Ershler. 1996. Inhibition of NFκB activity through maintenance of IκBα levels contributes to dihydrotestosterone-mediated repression of the interleukin-6 promoter. J. Biol. Chem. 271: 26267-26275.
53. Welte, T., F. Koch, G. Schuler, J. Lechner, W. Doppler, and C. Heufler. 1997. Granulocyte-macrophage colony-stimulating factor induces a unique set of STAT factors in murine dendritic cells. Eur. J. Immunol. 27: 2737-2740. (Pubitemid 27453868)
54. Feldman, G. M., L. A. Rosenthal, X. Liu, M. P. Hayes, A. Wynshaw-Boris, W. J. Leonard, L. Hennighausen, and D. S. Finbloom. 1997. STAT5A-deficient mice demonstrate a defect in granulocyte-macrophage colony-stimulating factor-induced proliferation and gene expression. Blood 90: 1768-1776.
55. Kieslinger, M., I. Woldman, R. Moriggl, J. Hofmann, J. C. Marine, J. N. Ihle, H. Beug, and T. Decker. 2000. Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev. 14: 232-244. (Pubitemid 30070988)
56. Laouar, Y., T. Welte, X. Y. Fu, and R. A. Flavell. 2003. STAT3 is required for Flt3L-dependent dendritic cell differentiation. Immunity 19: 903-912. (Pubitemid 37542309)
57. Onai, N., A. Obata-Onai, R. Tussiwand, A. Lanzavecchia, and M. G. Manz. 2006. Activation of the Flt3 signal transduction cascade rescues and enhances type I interferon-producing and dendritic cell development. J. Exp. Med. 203: 227-238. (Pubitemid 43139660)
58. Tse, K. F., G. Mukherjee, and D. Small. 2000. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14: 1766-1776.